GW Reed, JE Rossi, CP Cannon - The Lancet, 2017 - thelancet.com
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the …
J Stehli, C Martin, A Brennan, DT Dinh… - Journal of the …, 2019 - Am Heart Assoc
Background Timely revascularization with percutaneous coronary intervention (PCI) reduces death following myocardial infarction. We evaluated if a sex gap in symptom‐to‐door (STD) …
Human ESC-derived mesenchymal stem cell (MSC)-conditioned medium (CM) was previously shown to mediate cardioprotection during myocardial ischemia/reperfusion injury …
Background Recent reductions in average door-to-balloon (D2B) times have not been associated with decreases in mortality at the population level. We investigated this …
A Kumar, CP Cannon - Mayo Clinic Proceedings, 2009 - Elsevier
The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non—ST …
Writing Committee Members*, GN Levine, ER Bates… - Circulation, 2011 - Am Heart Assoc
The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted through November 2010, as well as selected …
CJ Terkelsen, JT Sørensen, M Maeng, LO Jensen… - Jama, 2010 - jamanetwork.com
Context Timely reperfusion therapy is recommended for patients with ST-segment elevation myocardial infarction (STEMI), and door-to-balloon delay has been proposed as a …
G De Luca, H Suryapranata, JP Ottervanger… - Circulation, 2004 - Am Heart Assoc
Background—Although the relationship between mortality and time delay to treatment has been demonstrated in patients with acute ST-segment elevation myocardial infarction …